The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women

Breast Journal

Volumn 10, Issue 3, 2004, Pages 211-217

  Buzdar, Aman U ^a   Vergote, Ignace ^b   Sainsbury, Richard ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Advanced breast cancer; Anastrozole; Aromatase inhibitors; Endocrine treatment; Estrogen receptor; Hormone receptor status; Letrozole; Progesterone receptor

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGE; BREAST CANCER; CLINICAL TRIAL; DISEASE COURSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; CONFIDENCE INTERVALS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; ODDS RATIO; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 2642510629     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21320.x     Document Type: Review

References (15)

1. Brodie AMH, Njar VCO. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 1998;66:1-10.
2. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;10:1371-88.
3. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-52.
4. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer; double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
5. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double-blind trial. J Clin Oncol 2000;18:1399-411.
6. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. J Clin Oncol 2000;18:3758-76.
7. Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (Tamoxifen or Arimidex™ Randomised Group Efficacy and Tolerability) study. J Clin Oncol 2000;18:3748-57.
8. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-602.
9. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B, for the Arimidex Writing Committee on behalf of the Investigators. Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women survival analysis and updated safety results. Eur J Cancer 2003;39:1684-89.
10. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
11. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer 1984;53:630-43.
12. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998;351(9114):1451-67.
13. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28-34.
14. Dirix L, Piccart MJ, Lohrisch C, et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in first-line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn [abstract 114]. 37th American Society of Clinical Oncology Annual Meeting, San Francisco, CA, 2001.
15. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole (Arimidex) is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast cancer. results of two randomised trials designed for combined analysis. Cancer 2001;92:2248-58.